177 related articles for article (PubMed ID: 11948260)
21. The applications of PET in clinical oncology.
Strauss LG; Conti PS
J Nucl Med; 1991 Apr; 32(4):623-48; discussion 649-50. PubMed ID: 2013803
[TBL] [Abstract][Full Text] [Related]
22. Extranodal manifestations of lymphoma on [¹⁸F]FDG-PET/CT: a pictorial essay.
Kashyap R; Rai Mittal B; Manohar K; Balasubramanian Harisankar CN; Bhattacharya A; Singh B; Malhotra P; Varma S
Cancer Imaging; 2011 Nov; 11(1):166-74. PubMed ID: 22123338
[TBL] [Abstract][Full Text] [Related]
23. [A proposal for the rational use of the PET in oncology].
Borrego Dorado I; Vázquez Albertino R
Rev Esp Med Nucl; 2002 May; 21(3):163-73. PubMed ID: 12206749
[TBL] [Abstract][Full Text] [Related]
24. Positron emission tomography for benign and malignant disease.
Visioni A; Kim J
Surg Clin North Am; 2011 Feb; 91(1):249-66. PubMed ID: 21184913
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of intrathoracic lesions detected by 18F-fluorodeoxyglucose positron emission tomography in the management of patients with head and neck cancer.
Roh JL; Ryu CH; Kim JS; Lee JS; Choi SH; Nam SY; Kim SY
Oral Oncol; 2007 Sep; 43(8):757-63. PubMed ID: 17112773
[TBL] [Abstract][Full Text] [Related]
26. PET in oncology: will it replace the other modalities?
Hoh CK; Schiepers C; Seltzer MA; Gambhir SS; Silverman DH; Czernin J; Maddahi J; Phelps ME
Semin Nucl Med; 1997 Apr; 27(2):94-106. PubMed ID: 9144854
[TBL] [Abstract][Full Text] [Related]
27. FDG PET in head and neck cancer.
Keyes JW; Watson NE; Williams DW; Greven KM; McGuirt WF
AJR Am J Roentgenol; 1997 Dec; 169(6):1663-9. PubMed ID: 9393187
[TBL] [Abstract][Full Text] [Related]
28. [Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000].
Hellwig D; Ukena D; Paulsen F; Bamberg M; Kirsch CM;
Pneumologie; 2001 Aug; 55(8):367-77. PubMed ID: 11505288
[TBL] [Abstract][Full Text] [Related]
29. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI.
Nowak B; Di Martino E; Jänicke S; Cremerius U; Adam G; Zimny M; Reinartz P; Büll U
Nuklearmedizin; 1999; 38(8):312-8. PubMed ID: 10615664
[TBL] [Abstract][Full Text] [Related]
31. Staging of head and neck squamous cell cancer with extended-field FDG-PET.
Schwartz DL; Rajendran J; Yueh B; Coltrera M; Anzai Y; Krohn K; Eary J
Arch Otolaryngol Head Neck Surg; 2003 Nov; 129(11):1173-8. PubMed ID: 14623746
[TBL] [Abstract][Full Text] [Related]
32. [Role of 18F-FDG positron emission tomography in surgical evaluation].
Franzius C; Sciuk J; Schober O
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():261-9. PubMed ID: 9931622
[TBL] [Abstract][Full Text] [Related]
33. 18-Fluorodeoxyglucose imaging in oncology.
Harolds JA
J Okla State Med Assoc; 1999 Sep; 92(9):457-61. PubMed ID: 10504797
[TBL] [Abstract][Full Text] [Related]
34. Comparison of (11)C-choline and (18)F-FDG PET in primary diagnosis and staging of patients with thoracic cancer.
Pieterman RM; Que TH; Elsinga PH; Pruim J; van Putten JW; Willemsen AT; Vaalburg W; Groen HJ
J Nucl Med; 2002 Feb; 43(2):167-72. PubMed ID: 11850480
[TBL] [Abstract][Full Text] [Related]
35. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer.
Pelosi E; Deandreis D
Eur J Surg Oncol; 2007 Feb; 33(1):1-6. PubMed ID: 17126522
[TBL] [Abstract][Full Text] [Related]
36. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
[TBL] [Abstract][Full Text] [Related]
37. [The role of positron emission tomography with C18-Fluorodeoxyglucose in clinical oncology].
Granov AM; Tiushin LA; Tlostanova MS; Kostenikov NA; Ryzhkova DV; Savello VE; Stanzhevskiĭ AA
Vopr Onkol; 2003; 49(5):563-73. PubMed ID: 14682126
[TBL] [Abstract][Full Text] [Related]
38. Development of oncology protocol using fluorine-18-FDG: one center's experience.
Cronin V; Galantowicz P; Nabi HA
J Nucl Med Technol; 1997 Mar; 25(1):66-9. PubMed ID: 9239608
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET.
Kalff V; Hicks RJ; Ware RE; Greer B; Binns DS; Hogg A
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):506-15. PubMed ID: 11914889
[TBL] [Abstract][Full Text] [Related]
40. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.
Kumar R; Xiu Y; Zhuang HM; Alavi A
Br J Dermatol; 2006 Aug; 155(2):357-63. PubMed ID: 16882175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
